Mike Youle

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1

Gerd Fätkenheuer, Anton Pozniak, Margaret Johnson et al. · Nature Medicine · 2005 · 490 citations

Treatment And Prevention, Medicine, Immunology +10

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

Mike Westby, Marilyn Lewis, Jeannette M. Whitcomb et al. · Journal of Virology · 2006 · 330 citations · Full text

Ccr5 Antagonist Maraviroc, Ccr5 Tropic, Human Retrovirus +11

Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy

Helen Devereux, Mike Youle, Margaret Johnson et al. · AIDS · 1999 · 285 citations

Late presenters in the era of highly active antiretroviral therapy

Caroline Sabin, Colette Smith, Helen Gumley et al. · AIDS · 2004 · 213 citations

Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 Trial

Ulrik Bak Dragsted, Jan Gerstoft, Court Pedersen et al. · The Journal of Infectious Diseases · 2003 · 118 citations · Full text

Assigned Treatment, Adverse Events, Indinavir/ritonavir Versus Saquinavir/ritonavir +13